本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Theravance Biopharma Inc.

9.50
+0.19002.04%
成交量:2,612.00
成交额:2.46万
市值:4.70亿
市盈率:-8.23
高:9.50
开:9.43
低:9.38
收:9.31
数据加载中...
2025/03/07

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/27

重要事件披露

Form 8-K - Current report
2025/01/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/09/23

重要事件披露

Form 8-K - Current report
2024/09/10

重要事件披露

Form 8-K - Current report
2024/09/09

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/08/09

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/05

重要事件披露

Form 8-K - Current report
2024/06/11

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/05/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/09

重要事件披露

Form 8-K - Current report
2024/05/03

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/03/05

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/01

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]